The PhytoIntelligence Blueprint Equation ($B_{1.7}$)

A Pseudomath Framework for Precision Phytotherapy

Marie-Soleil Seshat Landry, CEO & Spymaster

October 2025

The Governing Equation

The generation of a Precision Phytotherapy Blueprint ($B_{1.7}$) is defined as the summation of three sequential optimization phases:

$$B_{1.7} = \sum(\Phi_I \to \Phi_{II} \to \Phi_{III}) \cdot \epsilon \tag{1}$$

Where:

- Φ_I: Foundational Research & Precision Hypothesis Generation
- Φ_{II}: Preclinical Risk & Safety Vetting
- Φ_{III}: Reporting, PICO Protocol, & Structured Evidence
- ϵ: Evidence Density Constant ($\epsilon \geq 3$ distinct citations per variable)

Phase I: Foundational Research (Φ_I)

This phase calculates the core biological and chemical inputs required to address a specific disease target.

$$\Phi_I = [T_M + C_S + V_V] \times (P_G \cdot P_H) + H_{DEL} \tag{2}$$

Variable Descriptions:

T_M **(Target Mechanism):** Identification of ≥ 2 validated pathophysiological targets.

C_S **(Compound Screening):** Systematic screening of ≥ 7 phytochemical candidates.

V_V **(v1.7 Vector Ranking):** Ranking top 5-7 candidates by RCT count, efficacy, and bioavailability.

P_G **(Pharmacogenomic Vetting):** SNP-based risk assessment (e.g., CYP450, MTHFR).

P_H **(Phenotype Refinement):** Dose titration (H_{Dose}) based on patient-specific biomarkers.

H_{DEL} **(Advanced Delivery):** Selection of Nanodelivery systems (Liposomal, SLN, Polymeric).

Phase II: Preclinical & Safety Analysis (Φ_{II})

Phase II acts as a safety filter, ensuring the theoretical hypothesis is viable within human biological constraints.

$$\Phi_{II} = \frac{DNI + SSR + R_V}{E_M + C_M} \tag{3}$$

Variable Descriptions:

DNI **(Drug-Nutrient Interaction):** Mapping interactions with the top 5 standard-of-care medications.

SSR **(Safety Status Review):** Comparison of H_{Dose} against NOAEL/LOAEL safety levels.

R_V **(Regulatory Vetting):** Verification of GRAS, FDA, and EFSA status.

E_M **(Excipient Matrix):** Assessment of chemical stability and matrix compatibility.

C_M **(Clinical Monitoring):** Benchmarking against current Phase II/III clinical trials.

Phase III: Reporting & Protocol (Φ_{III})

The final phase structures the data into a manufacturable and testable scientific blueprint.

$$\Phi_{III} = R_S + PICO + T_C + [D!] \tag{4}$$

Variable Descriptions:

R_S **(Structured Report):** Compilation into a formal peer-reviewed style document.

$PICO$**:** Patient, Intervention, Comparison, and Outcome framework for clinical validation.

T_C **(Tiered Citations):** Organization of evidence into Tier 1 (RCTs) through Tier 3 (Preclinical).

$[D!\ (Conclusion \& Disclaimer) :] Mandatory disclosure of the B1.7 status as a hypothesis.$

Mandate: All facts must be supported by ≥ 20 verified references per blueprint.